Valproic acid downregulates Cdk5 activity via the transcription of the p35 mRNA

Biochemical and Biophysical Research Communications

Volumn 447, Issue 4, 2014, Pages 678-682

  Takahashi, Miyuki ^a   Ishida, Manami ^a   Saito, Taro ^a   Ohshima, Toshio ^b   Hisanaga, Shin Ichi ^a  

^a TOKYO METROPOLITAN UNIVERSITY   (Japan)

^b WASEDA UNIVERSITY   (Japan)

Author keywords

Autism; Cdk5; HDAC; p35; Transcription; Valproic acid

Indexed keywords

CYCLIN DEPENDENT KINASE 5; HISTONE DEACETYLASE; MESSENGER RNA; PROTEIN P35; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; IN VIVO STUDY; MOUSE; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RNA TRANSCRIPTION;

AUTISM; CDK5; HDAC; P35; TRANSCRIPTION; VALPROIC ACID;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM AGENTS; CYCLIN-DEPENDENT KINASE 5; DOWN-REGULATION; EARLY GROWTH RESPONSE PROTEIN 1; HISTONE DEACETYLASE INHIBITORS; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; NEURONS; PHOSPHOTRANSFERASES; RNA, MESSENGER; TRANSCRIPTION, GENETIC; VALPROIC ACID;

EID: 84900385043     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.04.072     Document Type: Article

References (35)

1. M.J. Rogawski, and W. Löscher The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions Nat. Med. 10 2004 685 692
2. N. Gurvich, and P.S. Klein Lithium and valproic acid: parallels and contrasts in diverse signaling contexts Pharmacol. Ther. 96 2002 45 66
3. T. Chomiak, and B. Hu Alterations of neocortical development and maturation in autism: insight from valproic acid exposure and animal models of autism Neurotoxicol. Teratol. 36 2013 57 66
4. C.U. Johannessen Mechanisms of action of valproate: a commentatory Neurochem. Int. 37 2000 103 113
5. C.J. Phiel, F. Zhang, and E.Y. Huang et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen J. Biol. Chem. 39 2001 36734 36741
6. S.S. Newton, and R.S. Duman Chromatin remodeling: a novel mechanism of psychotropic drug action Mol. Pharmacol. 70 2006 440 443
7. J. Hsieh, and F.H. Gage Chromatin remodeling in neural development and plasticity Curr. Opin. Cell Biol. 17 2005 664 671
8. X.X. Tang, M.H. Robinson, and J.S. Riceberg et al. Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma Clin. Cancer Res. 10 2004 5837 5844
9. R. Dhavan, and T.-H. Tsai A decade of CDK5 Nat. Rev. Mol. Cell Biol. 2 2001 749 759
10. Z.H. Cheung, and N.Y. Ip The roles of cyclin-dependent kinase 5 in dendrite and synapse development Biotechnol. J. 2 2007 949 957
11. S. Hisanaga, and R. Endo Regulation and role of cyclin-dependent kinase activity in neuronal survival and death J. Neurochem. 6 2010 1309 1321
12. G.N. Patrick, P. Zhou, and Y.T. Kwon et al. P35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway J. Biol. Chem. 273 1998 24057 24064
13. T. Saito, K. Ishiguro, and R. Onuki et al. Okadaic acid-stimulated degradation of p35, an activator of CDK5, by proteasome in cultured neurons Biochem. Biophys. Res. Commun. 252 1998 775 778
14. S. Minegishi, A. Asada, and S. Miyauchi et al. Membrane association facilitates degradation and cleavage of the cyclin-dependent kinase 5 activators p35 and p39 Biochemistry 26 2010 5482 5493
15. T. Harada, T. Morooka, S. Ogawa, and E. Nishida ERK induces p35, a neuron-specific activator of Cdk5, through induction of Egr1 Nat. Cell Biol. 5 2001 453 459
16. E. Utreras, A. Futatsugi, and P. Rudrabhatla et al. Tumor necrosis factor-alpha regulates cyclin-dependent kinase 5 activity during pain signaling through transcriptional activation of p35 J. Biol. Chem. 284 2009 2275 2284
17. T. Ohshima, J.M. Ward, and C.G. Huh et al. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death Proc. Natl. Acad. Sci. USA 93 1996 11173 11178
18. T. Kawauchi, M. Shikanai, and Y. Kosodo Extra-cell cycle regulatory functions of cyclin-dependent kinases (CDK) and CDK inhibitor proteins contribute to brain development and neurological disorders Genes Cells 18 2013 176 194
19. A.H. Hawasli, D.R. Benavides, and C. Nguyen et al. Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation Nat. Neurosci. 10 2007 880 886
20. F. Sananbenesi, A. Fischer, and X. Wang et al. A hippocampal Cdk5 pathway regulates extinction of contextual fear Nat. Neurosci. 10 2007 1012 1019
21. K.O. Lai, A.S. Wong, and M.C. Cheung et al. TrkB phosphorylation by Cdk5 is required for activity-dependent structural plasticity and spatial memory Nat. Neurosci. 15 2012 1506 1515
22. F. Plattner, A. Hernández, and T.M. Kistler et al. Memory enhancement by targeting Cdk5 regulation of NR2B Neuron 81 2014 1070 1083
23. F.Y. Wei, K. Tomizawa, and T. Ohshima et al. Control of cyclin-dependent kinase 5 (Cdk5) activity by glutamatergic regulation of p35 stability J. Neurochem. 93 2005 502 512
24. T. Hosokawa, T. Saito, and A. Asada et al. Enhanced activation of Ca2+/calmodulin-dependent protein kinase II upon downregulation of cyclin-dependent kinase 5-p35 J. Neurosci. Res. 84 2006 747 754
25. J.M. Drerup, K. Hayashi, and H. Cui et al. Attention-deficit/ hyperactivity phenotype in mice lacking the cyclin-dependent kinase 5 cofactor p35 Biol. Psychiatry 12 2010 1163 1171
26. M. Yger, and J.A. Girault DARPP-32, Jack of all trades... master of which? Front. Behav. Neurosci. 5 2011 56
27. O. Engmann, T. Hortobágyi, and R. Pidsley et al. Schizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition Brain 134 2011 2408 2421
28. M. Yamada, T. Saito, and Y. Sato et al. Cdk5-p39 is a labile complex with the similar substrate specificity to Cdk5-p35 J. Neurochem. 102 2007 1477 1487
29. T. Saito, R. Onuki, and Y. Fujita et al. Developmental regulation of the proteolysis of the p35 cyclin-dependent kinase 5 activator by phosphorylation J. Neurosci. 23 2003 1189 1197
30. Z. Marinova, M. Ren, and J.R. Wendland et al. Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation J. Neurochem. 111 2009 976 987
31. J.P. Hu, J.W. Xie, and C.Y. Wang et al. Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways Brain Res. Bull. 85 2011 194 200
32. B.S. Li, L. Zhang, and J. Gu et al. Integrin α1β1-mediated activation of cyclin-dependent kinase 5 activity is involved in neurite outgrowth and human neurofilament protein H Lys-Ser-Pro tail domain phosphorylation J. Neurosci. 20 2000 6055 6062
33. C.L. Bowden Valproate Bipolar Disord. 5 2003 189 202
34. M. Fukuchi, T. Nii, and N. Ishimaru et al. Valproic acid induces up- or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions Neurosci. Res. 65 2009 35 43
35. T. Ohshima, C.A. Kozak, and J.W. Nagle et al. Molecular cloning and chromosomal mapping of the mouse gene encoding cyclin-dependent kinase 5 regulatory subunit p35 Genomics 15 1996 372 375